We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+29.29%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.47B
AUM Growth
+$451M
(+5%)
Cap. Flow
+$1.13B
Cap. Flow
% of AUM
11.96%
Top 10 Holdings %
Top 10 Hldgs %
21.59%
Holding
903
New
107
Increased
255
Reduced
393
Closed
103
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BPMC
Blueprint Medicines
BPMC
|
+$51.9M |
| 2 |
Merck
MRK
|
+$50.9M |
| 3 |
Danaher
DHR
|
+$45.3M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$37.8M |
| 5 |
JD.com
JD
|
+$37.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$103M |
| 2 |
Alibaba
BABA
|
+$98.6M |
| 3 |
Salesforce
CRM
|
+$62.5M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$59.4M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$48.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.61% |
| 2 | Technology | 20.94% |
| 3 | Consumer Discretionary | 8.9% |
| 4 | Financials | 8.59% |
| 5 | Communication Services | 7.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
576
Thomson Reuters
TRI
$45.1B
| $979K | 0.01% |
+13,717
| New | +$992K |
|
|
NBP
577
NovaBridge Biosciences American Depositary Shares
NBP
$202M
| $977K | 0.01% |
+32,624
| New | +$675K |
|
578
Snap
SNAP
$8.02B
| $973K | 0.01% |
41,415
-6,980
| -14% | -$124K |
|
579
HUTCHMED
HCM
$1.93B
| $965K | 0.01% |
+35,000
| New | +$759K |
|
580
TC Energy
TRP
$70.5B
| $936K | 0.01% |
21,980
-1,331
| -6% | -$59.7K |
|
581
Trip.com Group
TCOM
$28.5B
| $934K | 0.01% |
36,020
-10,080
| -22% | -$254K |
|
|
PBCT
582
DELISTED
People's United Financial Inc
PBCT
| $931K | 0.01% |
80,470
-13,463
| -14% | -$157K |
|
583
Franklin Resources
BEN
$17.3B
| $930K | 0.01% |
44,331
-179,175
| -80% | -$3.38M |
|
|
VG
584
PUT
DELISTED
Vonage Holdings Corporation
VG
| $915K | 0.01% |
+5,614,000
| New | +$50.4M |
|
585
TransUnion
TRU
$16.2B
| $914K | 0.01% |
10,498
-38,862
| -79% | -$3.1M |
|
586
Expeditors International
EXPD
$22.4B
| $895K | 0.01% |
11,776
-10,157
| -46% | -$742K |
|
587
Packaging Corp of America
PKG
$22.6B
| $887K | 0.01% |
8,886
+6,355
| +251% | +$604K |
|
|
DISCK
588
DELISTED
Discovery, Inc. Series C Common Stock
DISCK
| $885K | 0.01% |
45,954
-2,135
| -4% | -$41.8K |
|
589
Teledyne Technologies
TDY
$30.1B
| $881K | 0.01% |
+2,834
| New | +$932K |
|
590
Tyler Technologies
TYL
$13.7B
| $881K | 0.01% |
2,541
-3,712
| -59% | -$1.25M |
|
591
NetApp
NTAP
$34.2B
| $869K | 0.01% |
19,590
-6,543
| -25% | -$281K |
|
592
Dentsply Sirona
XRAY
$2.7B
| $869K | 0.01% |
19,715
-509,421
| -96% | -$21.5M |
|
593
Vornado Realty Trust
VNO
$7.54B
| $864K | 0.01% |
22,623
-39,725
| -64% | -$1.54M |
|
594
Lennar Class A
LEN
$21.1B
| $862K | 0.01% |
14,451
-8,965
| -38% | -$458K |
|
595
Mid-America Apartment Communities
MAA
$15.8B
| $861K | 0.01% |
7,507
-5,103
| -40% | -$575K |
|
596
Iron Mountain
IRM
$37.4B
| $851K | 0.01% |
32,595
-64,858
| -67% | -$1.64M |
|
597
Paycom
PAYC
$7.54B
| $850K | 0.01% |
2,744
-7,922
| -74% | -$2.11M |
|
|
REGI
598
DELISTED
Renewable Energy Group, Inc.
REGI
| $835K | 0.01% |
+33,676
| New | +$853K |
|
599
Teleflex
TFX
$5.94B
| $830K | 0.01% |
2,280
-1,065
| -32% | -$368K |
|
|
IPG
600
DELISTED
Interpublic Group of Companies
IPG
| $827K | 0.01% |
48,209
-262,547
| -84% | -$4.33M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2020 Portfolio in Review
As of Q2 2020, Candriam SCA held 903 positions worth $9.47B, up 5% from $9.02B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $1.13B of net new capital in Q2 2020, opening 107 new positions and adding to 255 existing holdings. Its largest new stake was JD.com: 744,410 shares worth $44.8M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 31% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $103M trimmed.
- Candriam SCA's largest Q2 2020 buy was JD.com: 744,410 shares worth $44.8M.
- Candriam SCA added most to Blueprint Medicines in Q2 2020, an estimated $51.9M increase.
- Candriam SCA's biggest Q2 2020 reduction was Regeneron Pharmaceuticals, cutting an estimated $103M.
- Candriam SCA fully exited Salesforce in Q2 2020, selling an estimated $62.5M.
- Candriam SCA's ten largest holdings make up 22% of its $9.47B portfolio in Q2 2020.
- Candriam SCA opened 107 new positions and closed 103 in Q2 2020.
- Candriam SCA's portfolio value rose 5% quarter-over-quarter to $9.47B.
Based on Candriam SCA's 13F filing for Q2 2020, filed 23 Jul 2020.